Ligand Pharmaceuticals (LGND) Receivables (2010 - 2026)
Ligand Pharmaceuticals (LGND) posted Receivables of $53.4 million for Q1 2026, down 10.43% sequentially from $59.6 million in Q4 2025, and up 38.69% YoY from $38.5 million in Q1 2025.
Ligand Pharmaceuticals (LGND) Receivables (2010 - 2026) Analysis & Trends
Ligand Pharmaceuticals has reported Receivables for 17 years, with the latest figure at $53.4 million in Q1 2026.
- Quarterly Receivables rose 38.69% year-over-year to $53.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $53.4 million (up 38.69% YoY) and the FY2025 annual result came in at $59.6 million, up 55.31% from the prior year.
- Receivables slipped to $53.4 million in Q1 2026 per LGND's latest filing, from $59.6 million in the prior quarter.
- Over five years, Receivables peaked at $65.2 million in Q3 2022 and troughed at $28.0 million in Q2 2023.
- A 5-year average of $42.0 million and a median of $38.4 million in 2024 frame the typical range for Receivables.
- The sharpest annual moves came in 2022 and 2025: Receivables tumbled 64.4% in 2022, then soared 67.73% in 2025.
- Over 5 years, Receivables stood at $30.4 million in 2022, then rose by 8.19% to $32.9 million in 2023, then climbed by 16.58% to $38.4 million in 2024, then soared by 55.31% to $59.6 million in 2025, then retreated by 10.43% to $53.4 million in 2026.
- According to Business Quant data, Receivables over the past three periods registered $53.4 million, $59.6 million, and $57.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.93 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.06 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.84 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 912.74 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 215.33 Mn |
| 10 | Ligand Pharmaceuticals | 5.87 Bn | 4.51 Bn | 60.48 Mn | 67.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 67.01 Mn |
| Mar 31, 2026 | 53.38 Mn |
| Dec 31, 2025 | 59.60 Mn |
| Sep 30, 2025 | 57.56 Mn |
| Jun 30, 2025 | 41.29 Mn |
| Mar 31, 2025 | 38.49 Mn |
| Dec 31, 2024 | 38.38 Mn |
| Sep 30, 2024 | 34.32 Mn |
| Jun 30, 2024 | 37.48 Mn |
| Mar 31, 2024 | 28.44 Mn |
| Dec 31, 2023 | 32.92 Mn |
| Sep 30, 2023 | 36.00 Mn |
| Jun 30, 2023 | 27.99 Mn |
| Mar 31, 2023 | 29.19 Mn |
| Dec 31, 2022 | 30.42 Mn |
| Sep 30, 2022 | 65.17 Mn |
| Jun 30, 2022 | 62.31 Mn |
| Mar 31, 2022 | 41.80 Mn |
| Dec 31, 2021 | 85.45 Mn |
| Sep 30, 2021 | 64.34 Mn |